Metyrapone (Su-4885) Tartrate is a potent and orally active11β-hydroxylaseinhibitor and anautophagyactivator, also inhibits the production ofaldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation ofmTORpathway, and interacts withPseudomonas putidacytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression^{[1][2][3][4][5]}.

11β-hydroxylase, Aldosterone, CYP450, Autophagy^[1][4][5]

Metyrapone (100 μM; 2 h) hyperactivates autophagy in HepG2, and delays the activation of apoptosis at severe endoplasmic reticulum (ER) stress^[5].

Metyrapone (25 or 50 mg/kg; SC, single dosage) decreases the stress-induced increase in plasma corticosterone levels, significantly impairs acquisition performance at high dosage, and increases open arm activity at low dosage^[1].

526.45

C₂₂H₂₆N₂O₁₃

908-35-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.